STOCK TITAN

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.

About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio


Seer, Inc.

NASDAQ:SEER

SEER Rankings

SEER Latest News

SEER Stock Data

137.02M
46.94M
7.25%
71.38%
4.26%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
REDWOOD CITY

About SEER

seer, inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. the company develops proteograph product suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. it intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. seer, inc. has a collaboration program agreement with discovery life sciences, llc; and commercial agreements with bruker scientific llc and thermo electron north america llc. the company was formerly known as seer biosciences, inc. and changed its name to seer, inc. in july 2018. seer, inc. was incorporated in 2017 and is headquartered in redwood